Abstract:e23134 Background: Precision oncology promises tailored cancer treatments, yet current methods often overlook individual patient variability. The AI-powered Case Matching Assistant (ACMA) system addresses this by utilizing real-world data (RWD) from over 100,000 clinical cases to personalize treatment strategies, considering genetic profiles, cancer types, treatment stages, and drug interactions. Methods: ACMA enhances the Large Language Model (LLM) with oncology-specific pretraining that encompasses both molecular and clinical data, ensuring a holistic understanding of patient profiles. It employs cosine similarity for multi-faceted case comparisons, integrating genetic, biomarker, and vital clinical information. Context-aware learning prompts fine-tune the LLM, generating recommendations that reflect the full spectrum of patient-specific data, from genetic variations to clinical histories and treatment responses, facilitating truly personalized treatment pathways. Results: Preliminary results show ACMA's tailored recommendations improve patient outcomes, with increased median survival rates and cost-effective treatment options. The system's 90% relevance match for clinical trial enrollment also expands access to novel therapies. In the absence of a standard treatment protocol for BRCA germline mutations in advanced lung cancer, ACMA provides crucial insights. For instance, a 36-year-old female with BRCA1 c.527del mutation achieved complete remission with a PFS of 38 months after a combination therapy trial. A 56-year-old male with a BRCA2 S1722Yfs*mutation saw partial remission and over 6 months PFS with olaparib. Another male patient, a smoker with concurrent BRCA2 G1712X and TP53 mutations, experienced partial remission following apatinib therapy. ACMA analyzed treatment data from similar genetic profiles and identified a targeted therapy that had shown efficacy in comparable cases. The oncologist used this information as a reference to adjust the treatment plan, resulting in a positive clinical outcome for the patient. This example underscores the potential of ACMA to provide actionable insights for personalized cancer care. Conclusions: Surpassing traditional single-feature matching, ACMA rapidly aligns multi-dimensional characteristics such as cancer type, disease stage, molecular data, and treatment phases. It customizes the interplay of these features with medical logic, delivering tailored outputs through the LLM. This approach offers an economical, convenient, and timely solution, setting a new benchmark in personalized oncology and establishing ACMA as a leader in the field. This distinctive advantage not only enhances patient outcomes but also establishes a formidable barrier to entry for competitors, solidifying ACMA's position at the forefront of oncology practice.

Rapid Personalized Chemotherapy Recommendation for Cancer Patients: an Interview with Shaohua Ma and Two Members of His Group

Multiplex Gene Quantification As Digital Markers for Extremely Rapid Evaluation of Chemo-Drug Sensitivity

Multiplex Gene Quantification As Digital Cancer Markers for Extremely Rapid Evaluation of Chemodrug Sensitivity

Precision Oncology and AI: the ACMA System for Personalized Treatment Matching Using Real-World Data.

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

A Transformative Technology Linking Patient’s mRNA Expression Profile to Anticancer Drug Efficacy

A superior strategy for single-cell mutational screening via multiplex-targeted QPCR using the BioMark HD microfluidic platform.

Multi-parameter Systematic Strategy Opinion That Predicts, Prevents, and Personalized Treats a Cancer

Automated real-world data integration improves cancer outcome prediction

Advancing Personalized Cancer Therapy: Onko_DrugCombScreen - A Novel Shiny App for Precision Drug Combination Screening

Clinical Challenges and AI Opportunities in Decision-Making for Cancer Treatment-Induced Cardiotoxicity

Accelerating precision anti-cancer therapy by time-lapse and label-free 3D tumor slice culture platform

Artificial intelligence-based collaborative filtering method with ensemble learning for personalized lung cancer medicine without genetic sequencing

Evaluating Physician-AI Interaction for Cancer Management: Paving the Path towards Precision Oncology

Review of Personalized Medicine and Pharmacogenomics of Anti-Cancer Compounds and Natural Products

Medical decision support system for cancer treatment in precision medicine in developing countries

The R.O.A.D. to precision medicine

Application and challenge of HER2DX genomic assay in HER2+ breast cancer treatment

Prediction of Treatment Recommendations Via Ensemble Machine Learning Algorithms for Non-Small Cell Lung Cancer Patients in Personalized Medicine

PTOLEMI: Personalized Cancer Treatment through Machine Learning-Enabled Image Analysis of Microfluidic Assays

Prediction of Cancer Patient Responses to Different Treatments Using Personalized Tumor Models or Models with Matching Genomic Profiles.